A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.

Agnès Portron,Paul Jordan, Kristy Draper, Christopher Muenzer,Daniel Dickerson,Thijs van Iersel,Carsten Hofmann

Clinical Therapeutics（2020）

引用 23|浏览14

暂无评分

摘要

Subcutaneous gantenerumab injections at speeds of 5 and 15 s were well tolerated in healthy volunteers and could enable at-home administration by patients with AD or their caregivers. ClinicalTrials.gov identifier: NCT02882009.

查看译文

关键词

amyloid-β,gantenerumab,monoclonal antibody,safety,subcutaneous,tolerability

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要